


Figure 1. Polymorph Form C




Figure 2. Polymorph Form B




Figure 3. Amorphous Phase A




Figure 4. XRPD of solids from various Solvents




Figure 5.




Figure 6.




Figure 7.




Figure 8.




Figure 9.




Figure 10.




Figure 11.




Figure 12. TGA (top) and DSC (bottom) for Amorphous Phase A




Figure 13.




Figure 14. TGA (top) and DSC (bottom) for Polymorph Form B




Figure 15. TGA (top) and DSC (bottom) for Polymorph Form C

Amorphous Phase A




Figure 16.

Form B




Figure 17.

Form C




Figure 18.



Absorbance
0.24
0.22
0.20
0.18
0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0.00
4000
3500
3000
2500
2000
1500
1000
500
Wavenumber (cm-1)

Figure 19.



Induction of CYPs
Fold Induction Verses Control
1250
1000
750
500
250
0
CYP3A4
CYP2C9
Vehicle
Rifampicin
Compound 1

Figure 20.



Plasma Concentrations of Compound Following Single Dose Administration
Plasma Conc (log ng/mL)
100000
10000
1000
100
10
0
4
8
12
16
20
24
Time (hr)
50 mg (n = 6)
150 mg (n = 6)
300 mgs (n = 6)
600 mgs (n = 6)
1000 mgs (n = 6)

Figure 21.



% Change in Leukotriene B4 Levels
(Single Dose Cohorts)
% Baseline
300
250
200
150
100
50
0
PRE
1
2
3
4
6
8
12
24
48
72
Hours
24 hr % of Baseline
135±32
37 ± 4.7
24 ± 4.4
23 ± 8.3
1.6 ± 0.98
1.9 ± 0.41
Placebo (n=8)
50 mg (n=6)
150 mg (n=6)
300 mg (n=6)
600 mg (n=6)
1000 mg (n=6)

Figure 22.



% Change in Urinary LTE4 Levels
(Single Dose Cohort)
Urinary LTE4
(% Baseline)
Hours
Placebo (n=10)
50 mg
150 mg
300 mg
600 mg
1000 mg
0
10
20
30
40
50
60
70
80
90
100
110
130
150
170
190
210
0 3 6 9 12 16 24 36 48 72

Figure 23.



Plasma Concentrations of Compound Following Multiple Dose Administration
Plasma Conc (ng/mL)
2000
1500
1000
500
0
0
24
48
72
96
120
144
168
192
216
240
264
288
312
Time (hr)

Figure 24.



Cohort 6 - 150 mg
% Change in LTB4 levels
(Multiple Dose Cohort)
% Baseline
225
200
175
150
125
100
75
50
25
0
PRE 2 4 6 8 12 24
0 2 4 6 8 12 24 48 72
Day 1
Day 11
P1
P2
P3
P4
P5
P6
P7
P8

Figure 25.